Codagen Biosciences
CCM-325 is an Inhibitor of Autophagy
- Mechanism of autophagy
- CCM-325 in combination with azacitidine
Scientific Publications:
Scientific Publications:
CCM-848,914,930: Translational Readthrough Inducing Drugs (TRIDs) for CFTR Nonsense Mutations
- Cystic Fibrosis Transmembrane Regulator (CFTR) Functioning
- activity of molecules NV848, NV914 and NV930
Scientific Publications:
- Pibiri, I. et al. Targeting nonsense: optimization of 1,2,4-oxadiazole TRIDs to rescue CFTR expression and functionality in cystic fibrosis cell model systems. Int. J. Mol. Sci. 21: 6420, 2020.
- Pibiri, I. et al. Exploring the readthrough of nonsense mutations by non-acidic ataluren analogs selected by ligand-based virtual screening. Eur. J. Med. Chem. 122: 429-435, 2016.
Scientific Publications:
- Pibiri, I. et al. Targeting nonsense: optimization of 1,2,4-oxadiazole TRIDs to rescue CFTR expression and functionality in cystic fibrosis cell model systems. Int. J. Mol. Sci. 21: 6420, 2020.
- Pibiri, I. et al. Exploring the readthrough of nonsense mutations by non-acidic ataluren analogs selected by ligand-based virtual screening. Eur. J. Med. Chem. 122: 429-435, 2016.
CCM-521: the most potent inhibitor of the human cGAS autoimmune regulator reported to date
- The cGAS-STING pathway
- CCM-521
Scientific Publications:
- Wiser, C. et al. Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells. Scientific Reports 10(1): 7604, 2020.
- Vincent, J. et al. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nature Communications 8: 750, 2017.
Scientific Publications:
- Wiser, C. et al. Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells. Scientific Reports 10(1): 7604, 2020.
- Vincent, J. et al. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nature Communications 8: 750, 2017.
CCM-011 is the most potent & direct pan-KRAS inhibitor reported to date
- KRAS GTPase cycle
- CCM-011
Scientific Publications:
- McCarthy, M.J. et al. Discovery of high-affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding. ACS Omega 4: 2921-2930, 2019.
- Gupta, A. et al. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate. Chem. Biol. Drug Des. 94(2): 1441-1456, 2019.
Scientific Publications:
- McCarthy, M.J. et al. Discovery of high-affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding. ACS Omega 4: 2921-2930, 2019.
- Gupta, A. et al. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate. Chem. Biol. Drug Des. 94(2): 1441-1456, 2019.
First-in-class nonallosteric activators of Sirtuin enzymes
- Honokiol binding to SIRT3
- SIRT3
Scientific Publications:
- Mechanism of Inhibition of the Human Sirtuin Enzyme SIRT3 by Nicotinamide: Computational and Experimental Studies. Xiangying Guan, Ping Lin, Eric Knoll, Raj Chakrabarti. PLOS ONE, 2014.
- Pillai, V. B. et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3, Nat. Commun. 6: 6656-6672, 2015.
Next generation ALK/EGFR Inhibitors
- Binding insight of Brigatinib in ALK
- Scaffold Collection: Rational Design
- a. Overcoming resistance mutations including G1202R/L1196M (ALK) and T790M/L858R/C797S (EGFR)
- b. Uses proprietary multi-million compound DNA-Encoded libraries
PDB: 6MX8
a. Overcoming resistance mutations including G1202R/L1196M (ALK) and T790M/L858R/C797S (EGFR)
b. Uses proprietary multi-million compound DNA-Encoded libraries